Mycrodose Therapeutics

Mycrodose Therapeutics is dedicated to helping fight the mental health global pandemic that impacts all ages, all ethnicities, all genders, and spans the entire globe. It is our mission to develop cutting-edge technologies and novel IP in order to bring more happiness, love, connection, and understanding to those suffering.

Recent News

  • Mycrodose Therapeutics Successfully Delivers Both Macro and Microdose Levels of Psilocin Using Core Drug Delivery Technologies

    San Diego, California--(Newsfile Corp. - May 10, 2022) - Mycrodose Therapeutics showed the ability to synthesize and stabilize psilocin in their laboratory for use in their IP-protected drug delivery systems. The company successfully delivered in vitro both macro and microdose levels of psilocin through human skin using their patch and lozenge technologies. Mycrodose Therapeutics ("Mycrodose"), a leading US pharmaceutical company specializing in the development of advanced drug delivery (ADD) technologies utilizing DEA Schedule I & III drugs and other...

    2022-05-10 8:47 AM EDT
  • Mycrodose Therapeutics Announces First Clinical Candidate for Ketamine-Based Drug Delivery Device for Oral Mucositis

    San Diego, California--(Newsfile Corp. - March 31, 2022) - Mycrodose Therapeutics ("Mycrodose"), a leading US pharmaceutical company specializing in the development of advanced drug delivery technologies utilizing DEA Schedule I & III drugs and other compounds, announced today their lead clinical drug delivery system with a ketamine-based treatment for oral mucositis associated with cancer patients undergoing chemotherapy and radiation therapy. Mycrodose's first clinical candidate, MDT-001, is a controlled and sustained-release soft ketamine-based lozenge with a potential for reducing pain, inflammation,...

    2022-03-31 4:32 PM EDT
  • Mycrodose Therapeutics Granted DEA and FDA Approval to Cultivate Psilocybin Mushrooms in the United States

    San Diego, California--(Newsfile Corp. - February 23, 2022) - Mycrodose Therapeutics ("Mycrodose"), a leading US pharmaceutical company specializing in the development of advanced drug delivery systems to treat cancer related conditions, mental health, and cognitive degenerative diseases, announced today the US Drug Enforcement Agency (DEA) and the US Food and Drug Administration (FDA) have approved the company to cultivate Psilocybe cubensis and synthesize five (5) Schedule I compounds under their Schedule I Research License. "We are so excited that the...

    2022-02-23 7:55 AM EST
  • Mycrodose Therapeutics Expands Scientific Advisory Board with the Addition of Dr. Yavorsky and Dr. Jacques

    San Diego, California--(Newsfile Corp. - December 14, 2021) - Mycrodose Therapeutics ("Mycrodose"), a leading US pharmaceutical company developing advanced drug delivery technologies for use with psychedelic compounds, is pleased to announce the appointment of Dr. Christian Yavorsky and Dr. Jacqueline Jacques to its Scientific Advisory Board. Dr. Yavorsky is a psychologist by training and has worked in clinical trials in the pharmaceutical industry for nearly twenty years. He has worked primarily in Phase II and III clinical trials in psychiatry...

    2021-12-14 5:05 AM EST
  • Mycrodose Therapeutics Successfully Completes Oversubscribed Private Placement to Expand Existing Patent Portfolio of Breakthrough Advanced Drug Delivery Technologies

    Mycrodose Therapeutics successfully closes oversubscribed seven-figure financing round.Financing was funded by multiple high profile institutional investors, VCs, and Psychedelic Funds, including; The Conscious Fund, Negev Capital, Ambria Capital, K2 & Associates, Empath Ventures, Supernode, Receptor Fund, and many high profiles Silicon Valley Executives. Mycrodose Therapeutics is widely recognized as the first company to bring Advanced Drug Delivery Technologies (ADD) into the Psychedelic Medicine Sector. Mycrodose is one of only a few private companies that has been granted a Schedule I...

    2021-09-21 5:55 AM EDT
  • Mycrodose Therapeutics Announces Expansion of Southern California Pharmaceutical Laboratory

    San Diego, California--(Newsfile Corp. - September 2, 2021) - Mycrodose Therapeutics, a US pharmaceutical company focused on developing advanced drug delivery systems for use with psychedelic compounds, announced today the expansion of their Southern California Pharmaceutical laboratory. Earlier this year, Mycrodose Therapeutics was approved by the United States Drug Enforcement Agency (DEA), State of California Attorney General's Research Advisory Board, and The US Food & Drug Administration (FDA) to research four (4) psychedelic comp

    2021-09-02 6:55 AM EDT